Hematology

Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Probability, Inflore, Dana–Farber Cancer Institute, Lymphatic system, PMID, BM, MD, Kaplan–Meier estimator, Society, Research, Hematology, Patient, Clinical, LDT, Multiple myeloma, Chromosomal translocation, Mortality, System, FDA, HIV disease progression rates, Disease, Incidence, Personal computer, Pathology, Liquid biopsy, Cell, Bone marrow, CTC, Risk, Chinese, Safety, CMMC, Resource, B cell, SMM, MSB, Silicon, Blood, ASH, MGUS, Medical imaging, Pharmaceutical industry, Medical device

HUNTINGDON VALLEY, Pa., Dec. 14, 2022 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the results of a study in which enumeration and genomic characterization of CTCs at varying stages of MM represents an invaluable tool to predict disease aggressiveness and pathology. This study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery1.

Key Points: 
  • This study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery1.
  • This type of blood cancer forms in plasma cells (PCs) located in the bone marrow (BM).
  • 1Dutta A, Alberge J-B, et al, MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology, Cancer Discov CD-22-0482.
  • * The Circulating Multiple Myeloma Cell (CMMC) test is a CLIA-accredited laboratory developed test from Menarini Silicon Biosystems in USA.

Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Probability, Inflore, Dana–Farber Cancer Institute, Lymphatic system, PMID, BM, MD, Kaplan–Meier estimator, Society, Research, Hematology, Patient, Clinical, LDT, Multiple myeloma, Chromosomal translocation, Mortality, System, FDA, HIV disease progression rates, Disease, Incidence, Personal computer, Pathology, Liquid biopsy, Cell, Bone marrow, CTC, Risk, Chinese, Safety, CMMC, Resource, B cell, SMM, MSB, Silicon, Blood, ASH, MGUS, Medical imaging, Pharmaceutical industry, Medical device

HUNTINGDON VALLEY, Pa., Dec. 14, 2022 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the results of a study in which enumeration and genomic characterization of CTCs at varying stages of MM represents an invaluable tool to predict disease aggressiveness and pathology. This study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery1.

Key Points: 
  • This study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery1.
  • This type of blood cancer forms in plasma cells (PCs) located in the bone marrow (BM).
  • 1Dutta A, Alberge J-B, et al, MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology, Cancer Discov CD-22-0482.
  • * The Circulating Multiple Myeloma Cell (CMMC) test is a CLIA-accredited laboratory developed test from Menarini Silicon Biosystems in USA.

COALFIRE FEDERAL EXPANDS NIH PARTNERSHIP WITH NHLBI CYBER AWARD

Retrieved on: 
Tuesday, December 13, 2022
NIH, FedRAMP, Heart, Lung, Risk management framework, Partnership, Hematology, Research, Risk management, RMF, Government, National Heart, Lung, and Blood Institute, BPA, CMMC, NHLBI, Degenerative disease, Health, Federal, Pharmaceutical industry, Medical device

WASHINGTON, Dec. 13, 2022 /PRNewswire/ -- In 2021, Coalfire Federal was one of six firms chosen to provide cybersecurity strategy, risk management, and assessment services to the National Institutes of Health (NIH). Under the terms of the potential five-year, $86 million NIH OCIO (Office of the Chief Information Officer) RMF (Risk Management Framework) BPA (Blank Purchasing Agreement), the Virginia-based company will provide cybersecurity risk management and authority to operate (ATO) services across the NIH's 27 institutes and centers through 2026. 

Key Points: 
  • This latest cybersecurity services award to Coalfire Federal will enable NHLBI to maintain operational readiness and accelerate its mission.
  • "As a relative newcomer directly supporting NIH, Coalfire Federal was chosen by NHLBI over incumbent NIH contractors which we attribute to our pure-play cyber expertise and capabilities, government and commercial experience, and national ability to protect federal systems and supply chains."
  • We look forward to a long and successful partnership with NHLBI and NIH."
  • To learn more about Coalfire Federal and how it can help your organization protect the mission, contact us at [email protected] or visit coalfirefederal.com .

CoImmune Announces Presentation of Results from Phase I/II Clinical Trial of CARCIK-CD19 in B-Cell Acute Lymphoblastic Leukemia at ASH Annual Meeting and Exposition

Retrieved on: 
Tuesday, December 13, 2022
Exposition, Phase, Hematology, Hematopoietic stem cell transplantation, American Society of Hematology, Pediatrics, B-ALL, Society, CIK, Patient, CR, HSCT, Monza, Acute lymphoblastic leukemia, Cell, Science, CAR, University, EFS, MRD, ASH, University of Milano-Bicocca, Risk, Pharmaceutical industry

DURHAM, N.C., Dec. 13, 2022 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the presentation of results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company's chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform, in pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who had relapsed following hematopoietic stem cell transplantation (HSCT). The results are being presented at the American Society of Hematology's (ASH) 64th Annual Meeting and Exposition held December 10-13 in New Orleans.

Key Points: 
  • The results are being presented at the American Society of Hematology's (ASH) 64th Annual Meeting and Exposition held December 10-13 in New Orleans.
  • "In the Phase I/II dose-finding study, CARCIK-CD19 cells demonstrated an excellent safety profile with anti-leukemia activity in heavily pretreated patients with B-ALL relapsed after HSCT.
  • Importantly, the persistence of these cells was associated with a longer duration of response and reduced risk of leukemia relapse."
  • CoImmune is also announcing the presentation two additional preclinical studies at the ASH Annual Meeting that evaluated the CAR-CIK strategy in acute myeloid leukemia (AML).

Soricimed Appoints Leading North American Cancer Researcher Dr. Siqing Fu to its Scientific Advisory Board

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Peptide, Paralysis, TRPV6, Oncology, Hematology, Food, II, MD, Regulation of tobacco by the U.S. Food and Drug Administration, University, Cancer, Section, Research, MD Anderson Cancer Center, Tongji Medical College, Disease, Division, Coronavirus Scientific Advisory Board (Turkey), Christian democracy, Pharmaceutical industry, NB

MONCTON, NB, Dec. 13, 2022 /CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, has appointed Dr. Siqing Fu, a North American leader in cancer research, to its Scientific Advisory Board.

Key Points: 
  • MONCTON, NB, Dec. 13, 2022 /CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, has appointed Dr. Siqing Fu, a North American leader in cancer research, to its Scientific Advisory Board.
  • "We are honoured to have Dr. Fu join our Scientific Advisory Board at this pivotal time for our company," said Robert Bruce, Chief Executive Officer of Soricimed.
  • "He brings extensive experience to the research table including investigational cancer therapies specifically in novel design for phase I and II clinical trials.
  • "I am pleased to be joining Soricimed as a scientific advisor," said Dr. Fu.

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma

Retrieved on: 
Monday, December 12, 2022
BCMA, ORR, B-cell maturation antigen, Society, Regeneron Pharmaceuticals, Patient, Multiple myeloma, Ohio State University, Assistant, Division, Bone marrow, B cell, ASH, Risk, Vaccine, Pharmaceutical industry, Hematology

TARRYTOWN, N.Y., Dec. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma. The results were part of a broader presentation of new and updated data from a Phase 1/2 trial and were shared at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

Key Points: 
  • Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
  • "At the recommended 200 mg dose in a pivotal Phase 2 trial, linvoseltamab demonstrated early, deep and durable responses in patients living with multiple myeloma who had been on at least three prior therapies, including those with higher risk and high disease burden.
  • These clinically meaningful outcomes at 12 weeks reinforce the positive linvoseltamab results seen in the Phase 1 dose escalation portion, and we look forward to seeing data from more patients and longer follow-up."
  • The ongoing, open-label, multicenter Phase 1/2 dose-escalation and dose-expansion trial is investigating linvoseltamab in patients with R/R multiple myeloma.

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
BCMA, III, Pneumonia, ORR, R, B-cell maturation antigen, Poster, Diagnosis, Society, Patient, Șaeș, CR, Steroid, American Society of Hematology, PFS, T-14 Armata, DOR, AE, Annual general meeting, History, Clinical trial, Neurotoxicity, CAR, Cytokine release syndrome, Cyclophosphamide, Infection, CRS, MRD, AES, Toxic shock syndrome, ASH, Pharmaceutical industry, Vaccine, Hematology

This poster reports for the first time the pivotal phase II safety and efficacy data of LUMMICAR STUDY 1.

Key Points: 
  • This poster reports for the first time the pivotal phase II safety and efficacy data of LUMMICAR STUDY 1.
  • Zevor-cel, a fully human autologous CAR T-cell product targeting B-cell maturation antigen (BCMA), is being evaluated for patients with R/R MM in LUMMICAR STUDY 1 (NCT03975907), an ongoing phase I/II clinical trial in China.
  • A total of 102patients with R/R MM were treated with zevor-cel at the dose of 150106 CAR+ T cells.
  • Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics, said: "We are delighted to present the pivotal phase II data from the LUMMICAR STUDY 1 of zevor-cel at the ASH Annual Meeting this year.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.